Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
Experts say the ACR/AAHKS 2022 guidelines for patients undergoing total hip replacement or total knee replacement have several limitations that limit the effectiveness of their recommendations.
Read Full NewsComplicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.
A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.
The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.
1.
On all CAR-T products, the FDA is calling for a new boxed warning.
2.
A study has developed molecular markers that predict meningioma recurrence.
3.
Brexpiprazole Safe, Effective in Early-Episode Schizophrenia
4.
AI can identify women at risk of breast cancer years in advance: Study
5.
Advances in TNBC; Mixed News in Lung Cancer Report; Pancreatic Cancer Overdiagnosis?
1.
A Visual Journey Through Penile Cancer: Examining the Impact of Photos
2.
Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy
3.
Unlocking the Immune Arsenal: A Revolution in Cancer Treatment
4.
The Growing Crisis of Aplastic Anemia: A Call for Action
5.
Interpreting Iron Studies: What Your Blood Results Really Mean
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge